secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-09-25T23:59:59+00:00
Accession:  0001104659-25-093436
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering prices $175M public offering; Sanofi invests $25M in concurrent private placement
--------------------------------------------------------------------------------

- Public offering of 18,959,914 shares at $9.23/share; expected gross ~$175M; net proceeds ~$164.1M.
- Sanofi subsidiary Aventis to invest $25M via private placement at same price, 2,708,559 shares.
- Combined net proceeds ~$187.4M; cash runway extended into 2029; closing expected Sep 26, 2025.
- Company reduced ATM program by $1.25M and suspended sales under that amount.
- Proceeds to advance preclinical/clinical development and for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000110465925093436/0001104659-25-093436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000110465925093436/tm2526946d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-093436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer